Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients
- Status
- RECRUITING
- Phase
- N/A
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
- Status
- RECRUITING
- Phase
- PHASE2
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2